The functional rescue provided by BPC 157 after spinal cord injury implies that BPC 157 therapy can impact all stages of the secondary injury phase
SLC7A11 inhibitor SLC7A11, the catalytic subunit of system xc , functions as a transporter responsible for cysteine influx into cells, a process pivotal for the survival and growth of cancer cells
BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026
Hu C, Yang J, Qi Z, Wu H, Wang B, Zou F, et al
6c), indicating that H 2 O 2 catalyzed by NP4 not only disrupted the redox balance within tumor cells but also diffused outside the cells, leading to more cascading reactions
The FOXO4-DRI peptide is designed to mimic a portion of the FOXO4 protein, but with a key difference: it competes with the natural FOXO4 protein for binding to the p53 protein